⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
GIP Receptor Agonism and Antagonism
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-30 — Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.: Large-scale phenomic MR analysis of GLP-1 × GIP factorial contrasts favors lower genetically predicted GIP (combined with higher GLP-1) for weight and cardiometabolic risk reduction without a bone-harm signal — genetic evidence informing the contested agonist-vs-antagonist GIPR development question. [human-observational] (novelty: 3)
- 2026-10-05 — Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries.: Structured narrative review reframes GIPR pharmacology as bidirectional — both sustained GIPR agonism (tirzepatide-type) and GIPR antagonism (maridebart cafraglutide-type) can lower body weight and augment GLP-1R-mediated weight loss via divergent central circuits (GABAergic/area postrema vs. hypothalamic GIPR networks); mechanistic synthesis of rodent circuit models plus clinical anti-obesity data, with human validation of the proposed mechanisms still incomplete. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries.
05-oct-2026
novelty 3
per-area 3
strengthens
Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.
30-jul-2026
novelty 3
per-area 3
strengthens